Primary navigation

    Moderiba

    Drug - Moderiba™ (ribavirin) [AbbVie Inc.]

    June 2014

    Therapeutic area - Hepatitis C

    Approval criteria

    Patients can not take metoclopramide oral tablets or oral solution.

    FDA approved indication

    • Patient must have a diagnosis of hepatitis C AND
    • Prescriber must documentation of genotype (to determine length of treatment) AND
    • Prescriber must provide a compelling reason why generic ribavirin cannot be used

    Quantity/Therapy limitations

    • Genotype 1, 4 = 48 weeks of therapy
    • Genotype 2, 3 = 24 weeks of therapy
    • HIV coinfection = 48 weeks of therapy

    Background information

    Moderiba™ (ribavirin, USP) is a nucleoside analogue indicated for the treatment of chronic hepatitis C (CHC) virus infection in combination with peginterferon alfa-2a in adults with compensated liver disease not previously treated with interferon alpha, and in CHC patients coinfected with HIV.

    Questions?

    MHCP Provider Call Center 651-431-2700 or 800-366-5411

    back to top